Kim Frisch

Kim Frisch

Auto-generated profile, based on publicly available information

Kim Frisch

Aarhus University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
NØNikolaj Worm Ørntoft
Nikolaj Worm Ørntoft
OMOle Lajord Munk
Ole Lajord Munk
KFKim Frisch
Kim Frisch
POPeter Ott
Peter Ott
SKSusanne Keiding
Susanne Keiding
MSMichael Sørensen
Michael Sørensen

27 March 2012 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
KFKim Frisch
Kim Frisch
SJSteen Jakobsen
Steen Jakobsen
MSMichael Sørensen
Michael Sørensen
OMOle Lajord Munk
Ole Lajord Munk
AAAage Kristian Olsen Alstrup
Aage Kristian Olsen Alstrup
SKSusanne Keiding
Susanne Keiding
Excretion of conjugated bile acids into bile is an essential function of the liver, and impairment of canalicular bile acid secretion leads to cholestatic liver injury. However, hepatic excretory function cannot be quantified in vivo because of the lack of suitable methods. Cholylsarcosine is an analog of the endogenous bile acid conjugate cholylglycine and exhibits characteristics in vivo that led us to hypothesize that the 11C-labeled form, that is, [N-methyl-11C]cholylsarcosine (11C-cholylsarcosine), would be a suitable PET tracer for quantification of hepatic excretory function. Methods: A method for radiosynthesis of 11C-cholylsarcosine was developed involving 11C-methylation of glycine followed by conjugation with cholic acid. Blood-to-liver uptake and liver-to-bile excretion were investigated in vivo by dynamic 11C-cholylsarcosine PET/CT of 2 anesthetized pigs. In pig 1, a second dynamic 11C-cholylsarcosine PET/CT examination was preceded by a high dose of the endogenous bile acid conjugate cholyltaurine to investigate possible inhibition of the transhepatocellular transport of 11C-cholylsarcosine. In pig 2, a second 11C-cholylsarcosine administration was given to determine the biodistribution of the tracer by means of 5 successive whole-body PET/CT recordings. Possible formation of 11C-metabolites was investigated by analysis of blood and bile samples from a third pig. Results: The radiochemical yield was 13% ± 3% (n = 7, decay-corrected) and up to 1.1 GBq of 11C-cholylsarcosine was produced with a radiochemical purity greater than 99%. PET/CT studies showed rapid blood-to-liver uptake and liver-to-bile excretion of 11C-cholylsarcosine, with radioactivity concentrations being more than 90 times higher in the bile ducts than in liver tissue. Cholyltaurine inhibited the transhepatocellular transport of 11C-cholylsarcosine, indicating that the tracer is transported by one or more of the same hepatic transporters as cholyltaurine. 11C-cholylsarcosine underwent an enterohepatic circulation and reappeared in liver tissue and bile ducts after approximately 70 min. There were no detectable 11C-metabolites in the plasma or bile samples, indicating that the novel conjugated bile acid 11C-cholylsarcosine was not metabolized in the liver or in the intestines. The effective absorbed dose of 11C-cholylsarcosine was 4.4 μSv/MBq. Conclusion: We have synthesized a novel conjugated bile acid analog, 11C-cholylsarcosine, and PET/CT studies on anesthetized pigs showed that the hepatic handling of tracer uptake from blood and excretion into the bile was comparable to that for the endogenous bile acid cholyltaurine. This tracer may be valuable for future studies of normal and pathologic hepatic excretory functions in humans.

7 May 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MSMichael Sørensen
Michael Sørensen
KFKim Frisch
Kim Frisch
DBDirk Bender
Dirk Bender
SKSusanne Keiding
Susanne Keiding

29 August 2011 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
MSMichael Sørensen
Michael Sørensen
KMKasper Sandager Mikkelsen
Kasper Sandager Mikkelsen
KFKim Frisch
Kim Frisch
LBLudvik Bass
Ludvik Bass
BBBo Martin Bibby
Bo Martin Bibby
SKSusanne Keiding
Susanne Keiding
Accurate quantification of regional liver function is needed, and PET of specific hepatic metabolic pathways offers a unique method for this purpose. Here, we quantify hepatic galactose elimination in humans using PET and the galactose analog 2-18F-fluoro-2-deoxy-d-galactose (18F-FDGal) as the PET tracer. Methods: Eight healthy human subjects underwent 18F-FDGal PET/CT of the liver with and without a simultaneous infusion of galactose. Hepatic systemic clearance of 18F-FDGal was determined from linear representation of the PET data. Hepatic galactose removal kinetics were determined using measurements of hepatic blood flow and arterial and liver vein galactose concentrations at increasing galactose infusions. The hepatic removal kinetics of 18F-FDGal and galactose and the lumped constant (LC) were determined. Results: The mean hepatic systemic clearance of 18F-FDGal was significantly higher in the absence than in the presence of galactose (0.274 ± 0.001 vs. 0.019 ± 0.001 L blood/min/L liver tissue; P < 0.01), showing competitive substrate inhibition of galactokinase. The LC was 0.13 ± 0.01, and the 18F-FDGal PET with galactose infusion provided an accurate measure of the local maximum removal rate of galactose (Vmax) in liver tissue compared with the Vmax estimated from arterio-liver venous (A-V) differences (1.41 ± 0.24 vs. 1.76 ± 0.08 mmol/min/L liver tissue; P = 0.60). The first-order hepatic systemic clearance of 18F-FDGal was enzyme-determined and can thus be used as an indirect estimate of galactokinase capacity without the need for galactose infusion or knowledge of the LC. Conclusion: 18F-FDGal PET/CT provides an accurate in vivo measurement of human galactose metabolism, which enables the quantification of regional hepatic metabolic function.

18 June 2020 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
PDF file
KKKristoffer Kjærgaard
Kristoffer Kjærgaard
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
KFKim Frisch
Kim Frisch
KVKarina Højrup Vase
Karina Højrup Vase
SKSusanne Keiding
Susanne Keiding
OMOle Lajord Munk
Ole Lajord Munk
Purpose: Copper is essential for enzymatic processes throughout the body. [64Cu]copper (64Cu) positron emission tomography (PET) has been investigated as a diagnostic tool for certain malignancies, but has not yet been used to study copper homeostasis in humans. In this study, we determined the hepatic removal kinetics, biodistribution and radiation dosimetry of 64Cu in healthy humans by both intravenous and oral administration. Methods: Six healthy participants underwent PET/CT studies with intravenous or oral administration of 64Cu. A 90 min dynamic PET/CT scan of the liver was followed by three whole-body PET/CT scans at 1.5, 6, and 20 h after tracer administration. PET data were used for estimation of hepatic kinetics, biodistribution, effective doses, and absorbed doses for critical organs. Results: After intravenous administration, 64Cu uptake was highest in the liver, intestinal walls and pancreas; the gender-averaged effective dose was 62 ± 5 μSv/MBq (mean ± SD). After oral administration, 64Cu was almost exclusively taken up by the liver while leaving a significant amount of radiotracer in the gastrointestinal lumen, resulting in an effective dose of 113 ± 1 μSv/MBq. Excretion of 64Cu in urine and faeces after intravenous administration was negligible. Hepatic removal kinetics showed that the clearance of 64Cu from blood was 0.10 ± 0.02 mL blood/min/mL liver tissue, and the rate constant for excretion into bile or blood was 0.003 ± 0.002 min− 1. Conclusion: 64Cu biodistribution and radiation dosimetry are influenced by the manner of tracer administration with high uptake by the liver, intestinal walls, and pancreas after intravenous administration, while after oral administration, 64Cu is rapidly absorbed from the gastrointestinal tract and deposited primarily in the liver. Administration of 50 MBq 64Cu yielded images of high quality for both administration forms with radiation doses of approximately 3.1 and 5.7 mSv, respectively, allowing for sequential studies in humans. Trial registration number: EudraCT no. 2016–001975-59. Registration date: 19/09/2016.

10 January 2022 in Hepatology
Verified
Journal Article
Open access
PDF file
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
LGLars Christian Gormsen
Lars Christian Gormsen
KKKristoffer Kjærgaard
Kristoffer Kjærgaard
MVMikkel Holm Vendelbo
Mikkel Holm Vendelbo
DMDitte Emilie Munk
Ditte Emilie Munk
POPeter Ott
Peter Ott
Background and Aims: Wilson’s disease (WD) is a genetic disease with systemic accumulation of copper that leads to symptoms from the liver and brain. However, the underlying defects in copper transport kinetics are only partly understood. We sought to quantify hepatic copper turnover in patients with WD compared with heterozygote and control subjects using PET with copper‐64 (64Cu) as a tracer. Furthermore, we assessed the diagnostic potential of the method. Approach and Results: Nine patients with WD, 5 healthy heterozygote subjects, and 8 healthy controls were injected with an i.v. bolus of 64Cu followed by a 90‐min dynamic PET scan of the liver and static whole‐body PET/CT scans after 1.5, 6, and 20 h. Blood 64Cu concentrations were measured in parallel. Hepatic copper retention and redistribution were evaluated by standardized uptake values (SUVs). At 90 min, hepatic SUVs were similar in the three groups. In contrast, at 20 h postinjection, the SUV in WD patients (mean ± SEM, 31 ± 4) was higher than in heterozygotes (24 ± 3) and controls (21 ± 4; p < 0.001). An SUV‐ratio of hepatic 64Cu concentration at 20 and 1.5 h completely discriminated between WD patients and control groups (p < 0.0001; ANOVA). By Patlak analysis of the initial 90 min of the PET scan, the steady‐state hepatic clearance of 64Cu was estimated to be slightly lower in patients with WD than in controls (p = 0.04). Conclusions: 64Cu PET imaging enables visualization and quantification of the hepatic copper retention characteristic for WD patients. This method represents a valuable tool for future studies of WD pathophysiology, and may assist the development of therapies, and accurate diagnosis.